Visit our USA website
Re:Cognition Health is proud to announce the launch of Kisunla™ (donanemab), a revolutionary Alzheimer’s treatment, for private patients at our specialist clinics. This follows the success of global phase 3 clinical trials for donanemab, which demonstrated its ability to slow the progression of Alzheimer’s disease. Re:Cognition Health holds the distinction of being the first clinic in Europe to deliver this pioneering therapy.
Breaking Barriers in Alzheimer’s Care
While Kisunla™ is not currently available through the NHS due to existing NICE guidelines, private patients can now access this life-changing treatment at Re:Cognition Health’s state-of-the-art centres. This milestone builds on the clinic’s instrumental role in the groundbreaking TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 clinical trials, which provided compelling evidence of donanemab’s efficacy.
The Trailblazer 2 phase 3 trial, a randomised, double-blind, placebo-controlled study, involved 1,736 participants, including 62 enrolled at Re:Cognition Health centres in London, Guildford, and Birmingham. Over an 18-month period, the trial demonstrated that donanemab slowed cognitive decline by 35% compared to a placebo. Functional decline which affects daily activities such as managing finances, pursuing hobbies, and driving, was reduced by 40%. Among participants in the earliest stages of Alzheimer’s, the results were even more remarkable, with a 60% reduction in disease progression.
How Kisunla™ Works
Kisunla™ targets amyloid plaques, a hallmark of Alzheimer’s disease, by clearing these toxic proteins from the brain. Clinical trials revealed an average 84% reduction in amyloid plaque levels after 18 months of treatment, compared to just 1% in the placebo group. Administered as an intravenous infusion every four weeks, Kisunla™ provides a consistent and effective approach to combating Alzheimer’s progression.
Re:Cognition Health holds the distinction of being the first clinic in Europe to deliver this pioneering therapy.
Expert Insights
Dr Emer MacSweeney, CEO and Medical Director at Re:Cognition Health, served as the Principal Investigator for the TRAILBLAZER-ALZ 2 and 6 trials. Commenting on the availability of Kisunla™, she said:
“We are thrilled to offer Kisunla™ to private patients, marking a significant milestone in the fight against Alzheimer’s disease. As the first clinic in Europe to deliver this treatment, we are proud to continue leading the way in providing access to life-changing therapies. The results of the TRAILBLAZER-ALZ study highlight the importance of early intervention and the transformative potential of Kisunla™ for patients in the early stages of Alzheimer’s disease, also helping to pave the way for new medications.”
Continued Innovation at Re:Cognition Health
With unparalleled expertise in Alzheimer’s research, Re:Cognition Health ensures that patients receive the highest standard of care and access to the most advanced treatments. Alongside offering Kisunla, the clinic continues to lead groundbreaking clinical trials, providing patients with the opportunity to access new-generation therapies designed to slow or halt the progression of Alzheimer’s disease. Importantly, participation in these clinical trials is free, making these innovative treatments accessible to a wider population.
Re:Cognition Health remains committed to transforming Alzheimer’s care, offering hope to patients and families affected by this challenging condition. The introduction of Kisunla underscores the clinic’s dedication to staying at the forefront of medical advancements and ensuring that patients benefit from the latest breakthroughs in treatment.
To register interest or to find out more, please click here.
Information for Doctors and healthcare professionals only can be found here: https://recognitionhealth.com/leqembi-treatment-program-information-for-medical-professionals/
